نتایج جستجو برای: vx

تعداد نتایج: 1146  

Journal: :Antimicrobial agents and chemotherapy 2006
Robert B Perni Susan J Almquist Randal A Byrn Gurudatt Chandorkar Pravin R Chaturvedi Lawrence F Courtney Caroline J Decker Kirk Dinehart Cynthia A Gates Scott L Harbeson Angela Heiser Gururaj Kalkeri Elaine Kolaczkowski Kai Lin Yu-Ping Luong B Govinda Rao William P Taylor John A Thomson Roger D Tung Yunyi Wei Ann D Kwong Chao Lin

VX-950 is a potent, selective, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3-4A serine protease, and it demonstrated excellent antiviral activity both in genotype 1b HCV replicon cells (50% inhibitory concentration [IC50] = 354 nM) and in human fetal hepatocytes infected with genotype 1a HCV-positive patient sera (IC50 = 280 nM). VX-950 forms a covalent but reversible complex with...

2015
Helen Rice Christopher H. Dalton Matthew E. Price Stuart J. Graham A. Christopher Green John Jenner Helen J. Groombridge Christopher M. Timperley

To support the effort to eliminate the Syrian Arab Republic chemical weapons stockpile safely, there was a requirement to provide scientific advice based on experimentally derived information on both toxicity and medical countermeasures (MedCM) in the event of exposure to VM, VX or VM-VX mixtures. Complementary in vitro and in vivo studies were undertaken to inform that advice. The penetration ...

2008
S. W. Hulet D. R. Sommerville K. L. Matson C. L. Crouse J. A. Scotto B. J. Benton R. J. Mioduszewski S. A. Thomson

Constriction of the pupils (miosis) is often identified as the first noticeable sign of exposure to vapor nerve agents. We have previously identified that in minipigs there is a 30-40 fold difference in vapor dosages of sarin (GB) that elicit miosis vs. those vapor dosages that are potentially lethal. The ratio for miotic vs. lethal vapor dosages ranges from 100-135 fold when cyclo-sarin (GF) i...

Journal: :Basic <html_ent glyph="@amp;" ascii="&amp;"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&amp;"/> Toxicology 2006

Journal: :Molecular pharmacology 2017
Rhea P Hudson Jennifer E Dawson P Andrew Chong Zhengrong Yang Linda Millen Philip J Thomas Christie G Brouillette Julie D Forman-Kay

Understanding the mechanism of action of modulator compounds for the cystic fibrosis transmembrane conductance regulator (CFTR) is key for the optimization of therapeutics as well as obtaining insights into the molecular mechanisms of CFTR function. We demonstrate the direct binding of VX-809 to the first nucleotide-binding domain (NBD1) of human CFTR. Disruption of the interaction between C-te...

Journal: :Analytical chemistry 2006
Kanchan A Joshi Marek Prouza Maxwell Kum Joseph Wang Jason Tang Robert Haddon Wilfred Chen Ashok Mulchandani

An enzyme electrode for the detection of V-type nerve agents, VX (O-ethyl-S-2-diisopropylaminoethyl methylphosphonothioate) and R-VX (O-isobutyl-S-2-diethylaminoethyl methylphosphonothioate), is proposed. The principle of the new biosensor is based on the enzyme-catalyzed hydrolysis of the nerve agents and amperometric detection of the thiol-containing hydrolysis products at carbon nanotube-mod...

2013
Hong Yu Ren Diane E. Grove Oxana De La Rosa Scott A. Houck Pattarawut Sopha Fredrick Van Goor Beth J. Hoffman Douglas M. Cyr

Cystic fibrosis (CF) is a fatal genetic disorder associated with defective hydration of lung airways due to the loss of chloride transport through the CF transmembrane conductance regulator protein (CFTR). CFTR contains two membrane-spanning domains (MSDs), two nucleotide-binding domains (NBDs), and a regulatory domain, and its channel assembly requires multiple interdomain contacts. The most c...

Journal: :Thorax 2012
J P Clancy Steven M Rowe Frank J Accurso Moira L Aitken Raouf S Amin Melissa A Ashlock Manfred Ballmann Michael P Boyle Inez Bronsveld Preston W Campbell Kris De Boeck Scott H Donaldson Henry L Dorkin Jordan M Dunitz Peter R Durie Manu Jain Anissa Leonard Karen S McCoy Richard B Moss Joseph M Pilewski Daniel B Rosenbluth Ronald C Rubenstein Michael S Schechter Martyn Botfield Claudia L Ordoñez George T Spencer-Green Laurent Vernillet Steve Wisseh Karl Yen Michael W Konstan

BACKGROUND VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, has been shown to increase the cell surface density of functional F508del-CFTR in vitro. METHODS A randomised, double-blind, placebo-controlled study evaluated the safety, tolerability and pharmacodynamics of VX-809 in adult patients with cystic fibrosis (n=89) who were homozygous for the F508del-CFTR m...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2013
Kang-Yang Jih Tzyh-Chang Hwang

Vx-770 (Ivacaftor), a Food and Drug Administration (FDA)-approved drug for clinical application to patients with cystic fibrosis (CF), shifts the paradigm from conventional symptomatic treatments to therapeutics directly tackling the root of the disease: functional defects of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel caused by pathogenic mutations. The unde...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2004
Hans Minderman Kieran L O'Loughlin Lakshmi Pendyala Maria R Baer

PURPOSE The pipecolinate derivative VX-710 (biricodar; Incel) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1); we studied its activity against the third multidrug resistance (MDR)-associated drug efflux protein, breast cancer resistance protein (BCRP). EXPERIMENTAL DESIGN VX-710 modulation of uptake, retention, and cytotoxicity of mitoxant...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید